Upstream Bio (UPB) Free Cash Flow (2023 - 2026)
Upstream Bio (UPB) posted quarterly Free Cash Flow of -$47.9 million for Q1 2026, down 16.24% year-over-year from -$57.1 million in Q1 2025, and down 55.66% quarter-over-quarter from -$30.7 million in Q4 2025.
Upstream Bio (UPB) Free Cash Flow (2023 - 2026) Analysis & Trends
Upstream Bio's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$47.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 16.24% year-over-year to -$47.9 million; the TTM figure through Mar 2026 stood at -$140.1 million (down 68.46% YoY), while the FY2025 annual figure was -$133.4 million, down 123.58% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$47.9 million, down from -$30.7 million in the prior quarter.
- The five-year high for Free Cash Flow was -$8.0 million in Q2 2024, with the low at -$47.9 million in Q1 2026.
- The 4-year median for Free Cash Flow is -$21.1 million (2024), against an average of -$25.7 million.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow tumbled 388.29% in 2025, then fell 16.24% in 2026.
- Upstream Bio's Free Cash Flow stood at -$16.1 million in 2023, then decreased by 24.08% to -$20.0 million in 2024, then tumbled by 53.78% to -$30.7 million in 2025, then sank by 55.66% to -$47.9 million in 2026.
- Business Quant data shows UPB's Free Cash Flow at -$47.9 million in Q1 2026, -$30.7 million in Q4 2025, and -$22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | -35.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.62 Mn |
| Jun 30, 2026 | -35.62 Mn |
| Mar 31, 2026 | -47.85 Mn |
| Mar 31, 2026 | -47.85 Mn |
| Dec 31, 2025 | -30.74 Mn |
| Dec 31, 2025 | -30.74 Mn |
| Sep 30, 2025 | -22.25 Mn |
| Sep 30, 2025 | -22.25 Mn |
| Jun 30, 2025 | -39.24 Mn |
| Jun 30, 2025 | -39.24 Mn |
| Mar 31, 2025 | -41.17 Mn |
| Mar 31, 2025 | -41.17 Mn |
| Dec 31, 2024 | -19.99 Mn |
| Dec 31, 2024 | -19.99 Mn |
| Sep 30, 2024 | -13.96 Mn |
| Sep 30, 2024 | -13.96 Mn |
| Jun 30, 2024 | -8.04 Mn |
| Jun 30, 2024 | -8.04 Mn |
| Mar 31, 2024 | -17.56 Mn |
| Mar 31, 2024 | -17.56 Mn |